The trajectory of Sildenafil presents a complex picture for shareholders. While the initial launch generated substantial returns, the end of its intellectual property protection opened the floodgates to cheaper https://bookmarklinking.com/story11719497/the-copyright-and-big-pharma-a-volatile-investment